Information de reference pour ce titreAccession Number: | 00002953-200401000-00027.
|
Author: | Stanbrook, Matthew B. MD; Corey, Mary PhD; Tullis, D. Elizabeth MD, FCCP
|
Institution: | *From the Adult Cystic Fibrosis Program, St. Michael's Hospital (Dr. Tullis); the Asthma and Airway Centre, University Health Network (Dr. Stanbrook); the Division of Respirology, University of Toronto (Drs. Stanbrook and Tullis); the Hospital for Sick Children Research Institute (Dr. Corey); the Institute for Clinical Evaluative Sciences in Ontario (Dr. Stanbrook); and the Clinical Epidemiology Program, Department of Health Policy, Management, and Evaluation, University of Toronto (Drs. Stanbrook, Corey, and Tullis), Toronto, ON, Canada.
|
Title: | |
Source: | Chest. 125(1):150-155, January 2004.
|
Abstract: | Study objective: To determine the repeatability of measurements of FEV1 in adults with lung disease due to cystic fibrosis (CF).
Design: Single cohort study nested within a randomized controlled trial.
Setting: Adult CF of a university teaching hospital. Subjects were participants in a randomized trial of an experimental mucolytic drug.
Patients: Twenty-one adults (mean age, 27.5 +/- 9.2 years [+/- SD]) with CF and mild-to-moderate airflow obstruction (FEV1 70 +/- 15% predicted). Patients were in clinically stable condition prior to and during the study.
Interventions: Repeated FEV1 measurements were obtained at specific times of the day for 9 consecutive days, for a total of 31 measurements from each subject. Statistical measures of repeatability were calculated. Variation over the course of 1 day and variation from 1 day to the next were examined separately.
Measurements and results: For day-to-day FEV1 measurements, the within-subject SD was 0.145 L (4.5% of predicted), indicating greater variation compared to values previously established in normal subjects. The coefficient of repeatability indicated that day-to-day measurements could differ by as much as 13% of predicted in the absence of clinical change. For measurements within a single day, variation was not observed to be greater than normal.
Conclusions: In adults with CF, day-to-day variation in FEV1 measurements is greater than normal and similar to that seen in other obstructive lung diseases. Changes in FEV1 over time in adults with CF can likely be interpreted using the same criteria that apply to asthma or COPD.
Copyright (C) 2004 by the American College of Chest Physicians
|
Author Keywords: | adult; cystic fibrosis; forced expiratory volume; reproducibility of results; respiratory function tests.
|
References: | 1 Davis PB. Clinical pathophysiology and manifestations of lung disease. In: Yankaskas JR, Knowles MR, eds. Cystic fibrosis in adults. Philadelphia, PA: Lippincott-Raven Publishers, 1999; 45-67
2 Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326:1187-1191
3 American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144:1202-1218
4 Hruby J, Butler J. Variability of routine pulmonary function tests. Thorax 1975; 30:548-553
5 Pennock BE, Rogers RM, McCaffree DR. Changes in measured spirometric indices: what is significant? Chest 1981; 80:97-99
6 Lewinsohn HC, Capel LH, Smart J. Changes in forced expiratory volumes throughout the day. BMJ 1960; 1:462-464
7 Cooper PJ, Robertson CF, Hudson IL, et al. Variability of pulmonary function tests in cystic fibrosis. Pediatr Pulmonol 1990; 8:16-22
8 American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995; 152:1107-1136
9 Tullis DE, Corey M, Dabora R, et al. A double blind, placebo-controlled dose-escalating, tolerability study of inhaled recombinant gelsolin in cystic fibrosis [abstract]. Pediatr Pulmonol 1998; S15:A265
10 Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-310
11 Chinn S. Repeatability and method comparison. Thorax 1991; 46:454-456
12 Chinn S. The assessment of methods of measurement. Stat Med 1990; 9:351-362
13 Oldham PD, Cole TJ. Estimation of the FEV1. Thorax 1983; 38:662-667
14 McCarthy DS, Craig DB, Cherniack RM. Intraindividual variability in maximal expiratory flow-volume and closing volume in asymptomatic subjects. Am Rev Respir Dis 1975; 112:407-411
15 Cochrane GM, Prieto F, Clark TJH. Intrasubject variability of maximal expiratory flow volume curve. Thorax 1977; 32:171-176
16 Chinn S, Britton JR, Burney PGJ, et al. Estimation and repeatability of the response to inhaled histamine in a community survey. Thorax 1987; 42:45-52
17 Spencer DA, Marshall T, Weller PH, et al. A superior method for assessing the reproducibility of pulmonary function measurements [abstract]. Am Rev Respir Dis 1992; 145:A253
18 Enright P. Reporting the reproducibility of spirometry results. Am Rev Respir Dis 1992; 146:1367-1368
19 Enright PL, Johnson LR, Connett JE, et al. Spirometry in the Lung Health Study: methods and quality control. Am Rev Respir Dis 1991; 143:1215-1223
20 Troyanov S, Ghezzo H, Cartier A, et al. Comparison of circadian variations using FEV1 and peak expiratory flow rates among normal and asthmatic subjects. Thorax 1994; 49:775-780
21 Nickerson BG, Lemen RJ, Gerdes CB, et al. Within-subject variability and per cent change for significance of spirometry in normal subjects and in patients with cystic fibrosis. Am Rev Respir Dis 1980; 122:859-866
|
Language: | English.
|
Document Type: | Clinical Investigations: Cystic Lung Disease.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0012-3692
|
NLM Journal Code: | 0231335, d1c
|
Annotation(s) | |